Results 91 to 100 of about 5,769,054 (297)

Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee [PDF]

, 1998
"GH DEFICIENCY in the human adult most commonly results from pituitary or peripituitary tumors and their treatment (1). The majority of these tumors are benign, and in a large series, pituitary adenoma was the commonest cause of adult hypopituitarism (2).
Tanaka, T, Sonksen, P.H., Christiansen, J.S., Hintz, R., Thorner, M., Bengtsson, B A, Laron, Z., Clemmons, D, Ho, K., Carlsson, L., Sizonenko, P, Christ, E R, Hintz, R, Sönksen, P H, Carlsson, L, Carroll, P V, Sizonenko, P., Tanaka, T., Carroll, Paul V., Laron, Z, Thorne, M, Sizonenko, Pierre-Claude, Christiansen, J S, Ho, K, Clemmons, David, Christ, Emanuel R., Bengtsson, B.A.   +26 more
core   +2 more sources

Frequency of Growth Hormone Deficiency in Children with Short Stature

مجله دانشکده پزشکی اصفهان, 2010
Background: Growth hormone deficiency is an important and treatable cause for short stature in early diagnosed cases. This study was conducted to determine the frequency of growth hormone deficiency in children with short stature referred. Methods:
Shideh Assar, Hajieh Shahbazian, Kourosh Riahi, Keramat Kheradmand   +3 more
doaj  

Diagnosing Growth Hormone Deficiency in Adults

International Journal of Endocrinology, 2012
Adult growth hormone (GH) deficiency is a recognised syndrome associated with adverse phenotypic, metabolic, and quality-of-life features which improve in many patients when GH is substituted.
Nigel Glynn, Amar Agha
doaj   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Growth hormone replacement in adults with growth hormone deficiency: assessment of current knowledge

, 2000
The recent availability of recombinant human growth hormone (GH) has led to intense investigation of the consequences of adult GH deficiency (GHD) and the effects of GH replacement.
Christ, E R, Sönksen, P H, Carroll, P V
core   +1 more source

Linear Growth in Children With Growth Hormone Deficiency: Interaction of Growth Hormone, Somatostatin and Amino Acids [PDF]

, 1990
Thirty two children (twenty one boys and eleven girls) whose ages ranged from 2.17 to 17.94 years were identified as having growth hormone deficiency. Of these, nineteen (fourteen boys and five girls) had idiopathic growth hormone deficiency, while in ...
Smeda, Smeda Hassan
core   +4 more sources

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

GROWTH HORMONE THERAPY FOR ADULT GROWTH HORMONE DEFICIENCY

International Journal of Clinical Practice, 1998
SUMMARYGrowth hormone deficiency in adult life is associated with a number of adverse biological changes which include osteopenia, reduced exercise capacity, altered body composition, deleterious alterations in the lipid profile and insulin status, and reduced quality of life. Most of these changes can be reversed by growth hormone replacement therapy,
openaire   +2 more sources

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Pharmocogenetic study on efficacy of recombinant growth hormone treatment in short stature patients with growth hormone deficiency

, 2009
[[abstract]]Growth hormone (GH) is the most important one to stimulate human body growth and it is especially significant for children before puberty.
Wei-Cheng Chen
core